NaPi2b targeting antibody-drug conjugates (ADC Therapeutics)

N/A

Report date: 2024/04/03 14:19:29

Base Information

Drug NameNaPi2b targeting antibody-drug conjugates (ADC Therapeutics)

Drug Alias NameNaPi2b-PL2202

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > VA linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) +[4]

Mechanisms of ActionSodium-dependent phosphate transport protein 2B inhibitors

TargetsSodium-dependent phosphate transport protein 2B

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySwitzerland

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesAdc Therapeutics Sa

China Registration ClassN/A

Develop Information

Active CompaniesAdc Therapeutics Sa

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A